| Item Number | Description | Schedule Fee |
|---|---|---|
| 73336 | A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. |
$230.95 |
| Total: | $230.95 | |